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The acquired immunodeficiency syndrome (AIDS)
caused by a retrovirus variously termed the human
immunodeficiency virus-1 (HIV-1), HTLV III or
Lymphadenopathy associated virus (LAV), is no
longer a rare or exotic disease. Since its first
description in June 1981 it is now a worldwide
pandemic. The World Health Organization (WHO)
estimates that there are 40 million people in the world
infected with HIV. Approximately 95 per cent of these
cases as well as deaths from AIDS occur in the
developing world.  However, autopsies are rarely
performed in the developing countries on patients with
HIV infection, hence our current understanding of
the pathology and pathophysiology of HIV infection
largely stems from studies of populations infected with
HIV cladeB virus in North America and Western
Europe. Of the various subtypes of HIV, subtype C
is responsible for >50 per cent of all HIV-1 infections
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Neurological manifestations of HIV infection and AIDS are being recognized with a frequency
that parallels the increasing number of AIDS cases. Next to sub-Saharan Africa, India has the
second largest burden of HIV related pathology, essentially caused by HIV-1 clade C in both the
geographic locales, in contrast to USA and Europe. But the true prevalence of HIV related
neuroinfections and pathology is not available due to inadequate medical facilities, social stigma
and ignorance that lead to underdiagnosis. Neurotuberculosis, followed by cryptococcosis and
toxoplasmosis in various combinations are the major neuropathologies reflecting the endemicity
and manifesting clinically by reactivation of latent infection. Discordance in the clinical
prevalence of various infections, when compared to pathological studies highlight similarities
in clinical, radiological modalities of diagnosis and inherent problems in establishing definitive
diagnosis. Viral infections appear to be relatively rare. Inspite of heavy burden of HIV/AIDS,
HIV associated neoplasia is infrequent, including primary CNS lymphomas.  HIV encephalitis
and HIV associated dementia are considered infrequent, though systematic studies have just
been initiated in various centres. Peripheral neuropathy characteristically manifests with
vasculitic neuropathy while diffuse infiltrative lymphocytosis syndrome (DILS) involving nerves
has not been reported from India. Spinal cord pathology including vacuolar myelopathy is rare,
even in asymptomatic cases. Till now the AIDS cases in India were drug naïve but a new cohort
of cases following initiation of HAART therapy as a national policy is soon emerging, altering
the biology and evolution of HIV/AIDS in India.  Lacunae in the epidemiology, diagnosis and
study of biology of HIV/AIDS are outlined for future research.
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causing rapidly growing epidemics in India, China,
Brazil, and southern and eastern parts of Africa. HIV-
clade C therefore infects the largest populations in the
world.  The subtype distribution in India was confirmed
to be predominantly clade C in a study that employed
a subtype-specific PCR1. Although important sequence
differences have been identified in functional domains
between the clades, whether these differences
translate into alteration in spectrum of pathological
manifestations remains unknown. Pathological
manifestations are also influenced by host genetic
factors and environmental factors unique to developing
countries. Hence a comparative analysis of the
pathological manifestations from different regions of
the world is necessary. Since antiretroviral drugs have
only recently been introduced in the developing
countries, and only in very select populations, we have
compared the neuropathological findings of patients in
India with the published literature from the pre-highly
active antiretroviral therapy (HAART) era.
In the early years of the epidemic, nervous system
involvement was not widely recognized. It is now
recognized that every level of the neuraxis can be
involved and at least one third of patients with
advanced HIV infection will develop neurological
complications during the course of their illness2,3, and
in 10 per cent of cases neurological problems may be
the first sign of development of AIDS. But at autopsy,
more than 80 per cent of patients show evidence of
cerebral pathology ranging from HIV encephalitis,
opportunistic infections or lymphomas and one half
will have some evidence of peripheral neuropathy4-6.
These figures hold true in countries with limited or
no access to antiretroviral drugs7,8 as well as in those
countries with full access to such drugs.
There is virological and clinical evidence to show
that the HIV is both lymphotropic and neurotropic.The
virus is both genetically and morphologically related to
visna, a retrovirus that affects sheep and is both
neurotropic and lymphotropic. Secondly the HIV viral
particles were recovered from cultures of cerebrospinal
fluid (CSF), brain and spinal cord9. The levels of HIV
specific IgG are higher in CSF than in serum implying
active CNS infection. Evidence of low grade infection
of the CNS can be demonstrated in asymptomatic
individuals within two years of seroconversion who
show pleocytosis, positive viral culture or a rise in IgG10.
Autopsies of patients at this stage reveal abnormalities
in 90 per cent of which the commonest is an
encephalitis in the absence of any cause other than
the HIV virus itself. Clinical evidence for a direct role
of the virus in neurological involvement is seen in the
appearance of meningitis at the time of seroconversion.
Viral sequence studies from the brain now suggest that
it may evolve within the brain and it may thus act as a
reservoir for the virus11-13.
The immune deficiency produced by the virus
makes patients susceptible to a plethora of
opportunistic infections that range from viruses, fungi,
parasites and a host of other pathogens newly
recognized or previously never considered significant.
In addition, the impairment of humoral as well as cell
mediated immunity alters the normal inflammatory
response to pathogens which translates clinically as
minimal signs of inflammation such as fever or
meningism, minimal pleocytosis in CSF even in the
presence of infection and defective antibody
production making diagnostic tests (that employ
antibody testing) of little use in diagnosis of infections.
The tissue response too is muted which alters brain
imaging characteristics and contrast enhancement.
Multiple pathogens can simultaneously cause
infections further complicating diagnosis and
treatment. In the presence of immunosuppression,
relapse is common and hence antimicrobial
prophylaxis needs to be lifelong.
Opportunistic infections (OI) are the most
important and common cause of mortality in HIV
infected individuals. Direct HIV infection of the CNS
also causes important clinical syndromes like AIDS
dementia complex (ADC), HIV encephalitis and
encephalopathy with minor and major cognitive
abnormalities. The CD4 cell count is a good predictor
of the likelihood of the specific disorders and virtually
provides a “time of reference” for prediction.
Opportunistic infections complicate the late stages of
HIV infection. In the early stages, conditions in which
there is a prominent inflammatory response such as
acute inflammatory demyelinating polyneuropathy, and
polymyositis are more common.
Though AIDS is fundamentally the same disease
all over the world, the spectrum of opportunistic
infections that occur is governed to a large extent by
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the endemicity of microorganisms prevalent in the
environment. Numerous microbial infections occur
with increased efficiency of transmission in the
background of HIV that includes bacterial, fungal,
parasitic and viral infections. Of these, only the
common opportunistic infections prevalent in India are
discussed here.
Fungal infections
Fungal infections involving the brain in the vast
majority are secondary to a primary focus elsewhere,
most often in the lungs or intestine. But the primary
focus remains unrecognized in most of the cases, and
the only evidence of infection at the time of
presentation would be in the nervous system.
Cryptococcal meningitis (CM): Among the fungal
infections affecting the CNS, CM due to
Cryptococcus neoformans is the most common HIV
associated complication both in developed and
developing countries14-16. Signs and symptoms of CNS
cryptococcal infections are often subtle and
nonspecific, evolving over days or weeks with often
only a mild headache as the presenting manifestation.
Focal neurological deficits, signs of meningeal
irritation and papilledema may be lacking and
radiological investigations including computed
tomography (CT) and magnetic resonance imaging
(MRI) non-contributory. The importance of being alert
to this condition lies in the fact that it is easily
treatable and diagnosis requires only a simple
examination of CSF to demonstrate the budding yeast
forms of the fungus. But if the diagnosis is missed,
the patient can deteriorate rapidly within hours to
days. A clinical aphorism often stated is that headache
in advanced HIV disease is cryptococcal meningitis
until proved otherwise. Cryptococcal meningitis
complicates AIDS when the CD4 counts fall below
100 cells/ul. Sex, race and other opportunistic
infections do not significantly alter the risk of CM in
HIV patients15.
Approximately 5-10 per cent of HIV infected
patients will develop CM as an AIDS defining illness17,
and in about 40 per cent patients, it may be the initial
manifestation of HIV infection18. There is however,
a wide geographic variation from 2 per cent in
Northern Europe to 20-30 per cent in Africa and South
East Asia19. In a preliminary analysis of 588 cases of
HIV infection (from 1990-2002) at the Neurological
services, National Institute of Mental Health and
Neurosciences (NIMHANS), Bangalore, south India,
cryptococcal infection was detected in 25 per cent
of cases, preceded by neurotuberculosis (30%), with
both cryptococcus and tuberculosis co-existing with
toxoplasmosis in 12 per cent of cases (Satishchandra
P, unpublished data). Another clinical series from
western India reported cryptococcal meningitis in 67.4
per cent of cases and tuberculous meningitis (TBM)
in 18.6 per cent of cases20.
On the other hand, in an autopsy series of
134 cases (between 1990-2004) from NIMHANS,
cryptococcal infection of nervous system topped the
list accounting for 31.3 per cent cases, followed by
toxoplasmosis (20.8%) and tuberculous meningitis in
20.1 per cent of cases as monomicrobial infections
(Shankar SK, unpublished data). The discrepancy
between the clinical and autopsy data could be
attributable to systemic cryptococcal infection
masquerading clinically and radiologically as
mycobacterial infection and the clinical bias because
of endemicity. Recognition of the entity of
‘cryptococcal primary complex’ similar to
Mycobacterium tuberculosis infection can provide
an insight into the biology of this infection. It is likely
that cryptococcal meningitis in cases of HIV could
be reactivation of the dormant lesion in the lung similar
to Ghon’s focus of pulmonary tuberculosis.
The fungus is a common soil contaminant being
excreted in feces of several birds particularly
pigeons. In HIV patients as well as in other
immunocompromised states, cryptococcal infection is
caused almost exclusively by the neoformans variant.
Infection occurs via inhalation and primary infection is
localized to the lung from where there is dissemination
to other organs including brain. The resulting lung
infection is usually asymptomatic. Spread to the brain
most often causes leptomeningitis very similar to
tuberculosis. The CSF facilitates establishment of
infection because it lacks complement and
immunoglobulins and thereby acts as a good culture
medium for the fungus. CNS involvement by the fungus
causes a leptomeningitis and uncommonly a
meningoencephalitis. Cryptococcomas (localized
granulomas) are extremely rare.
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In addition to nonspecific clinical complaints like
fever, altered mental status, nausea and vomiting, and
severe headache, elevated intracranial pressure (ICP)
is reported in excess of 50 per cent of HIV-1 infected
patients with CM21 without accompanying
hydrocephalus or cerebral oedema. A retrospective
study of 119 cases of Cryptococcus with HIV from
NIMHANS, south India, the cranial CT scanning
revealed features of cerebral atrophy in 19 per cent
and hydrocephalus in 10 per cent of cases
(unpublished data). In the study from NIMHANS,
nearly 90 per cent of cases of cryptococcal meningitis
manifested with “unbearable headache” with or
without mild fever resembling acute subarachnoid
haemorrhage. The severe headache abated
spontaneously after two to three weeks of antifungal
therapy, but did not respond to mannitol and steroid
therapy suggesting pathogenetic mechanisms other
than cerebral oedema is responsible for the headache
(Satishchandra P, unpublished observations). Saag
et al21 emphasized that elevated intracranial pressure
has been reported in excess of 50 per cent of HIV-1
infected patients with CM but in the absence of
accompanying hydrocephalus or cerebral oedema. An
opening CSF pressure of 250-350 mmH2O has been
recorded22. Importantly, clinical signs of raised
intracranial pressure were absent even in those
patients with highest pressures. The pathophysiology
of this increased ICP in the absence of associated
clinical signs has not been fully elucidated17. A
preliminary pathological study of the brain and the
dural venous sinuses in our autopsied cases
(unpublished data) revealed plugging of the arachnoid
villi by masses of cryptococci, at places almost
occluding the venous sinuses. This could be
responsible for impendence to CSF circulation leading
to dynamic hydrocephalic attacks, not recognized in
cranial CT scan or MRI in majority of instances.
Pathological examination of the brain in
cryptococcal meningitis typically shows mucinous
exudates covering the superolateral aspect of the
brain, unlike the basal exudates of tuberculous
arachnoiditis. It also produces multiple cystic non-
granulomatous parenchymal lesions in basal ganglia
and thalamus, and the cortical ribbon, which suggest
haematogenous spread of the fungus and entrapment
around the endarteries of the pial, lenticulostriate and
thalamostriate vessels especially with relatively long
duration of illness. Inflammatory response to the
fungus is characteristically sparse as the capsule of
the cryptococci inhibit phagocytosis and impair
leukocyte migration23. Giant cell reaction to the
cryptococci or granulomatous reaction to produce
cryptococcomas are not often seen. Rarely large
plaque like demyelinating lesions resembling
progressive multifocal encephalopathy (PML) on
imaging and gross pathology are seen. This probably
represents dispersal of the organisms along the
medullary veins, following blockage of superior
sagittal sinus and venous impedence.
Of the diagnostic modalities available,
cryptococcal antigen in CSF and serum is virtually
always positive except in very early stages of the
disease or in cryptococcomas. Sensitivity of India ink
test on CSF is approximately 70 per cent24. Fungal
culture is useful only for speciation of the organism
and sensitivity to antifungal agents.
In a comparative study of cryptococcal meningitis
with and without associated HIV from our centre25,
it was noted that poor CSF inflammatory cell
response, positive culture of cryptococci from
extraneural sites and systemic dissemination are
common when associated with HIV infection and
connote a poor prognosis. Clinical indicators of poor
prognosis include depressed level of consciousness,
development of signs of raised intracranial tension,
markedly depressed CSF glucose, CSF white cell
count below 20/mm3, and cryptococcal antigen titre
greater than 102415.
Other mycoses: Other mycoses documented in HIV/
AIDS include aspergillosis which produce multiple
abscesses and rarely granulomas, candidiasis also
causing abscesses in brain from haematogenous
dissemination from primary focus in respiratory or
gastrointestinal tract, and coccidioidomycosis
presenting as a basal meningitis causing
hydrocephalus or cerebellar or brain stem abscesses.
These are however extremely rare and confined
to case reports. Even rarer is involvement by
Nocardia asteroides , Histoplasma capsulatum
causing meningoencephalitis, zygomycosis, and
Cladosporium bantianum. Narendra Singh from
Manipur reported26  increased incidence of
Penicillium marneffei infection among patients with
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AIDS next to tuberculosis and Pneuomocystis
carninii pneumonia. Infection by this fungus is
commonly reported from Thailand where it is the third
commonest AIDS defining opportunistic infection. In
India, other than from Manipur, there are no reports
of this mycoses from anywhere else till date.
Protozoal infections
Cerebral toxoplasmosis: Cerebral toxoplasmosis is
the most common cause of cerebral mass lesion in
patients with AIDS. This is true even in the developing
world where tuberculosis is endemic and a frequent
cause of such lesions. The disease is eminently
treatable, most patients making a full recovery but is
fatal if untreated. In USA and Western Europe, nearly
10-30 per cent of HIV seropositive patients die of
toxoplasmosis27, although uncommon, cases of
toxoplasma encephalitis (TE) in patients who are
seronegative for HIV have also been reported27.
It is a protozoal parasitic disease prevalent
worldwide, its prevalence varying according to dietary
preferences in any country. For instance, in certain
parts of Europe, particularly France, very high
seroprevalence (70-90%) has been observed,
attributable to the habit of raw-meat eating, while in
the United States it is approximately 30 per cent28,29.
Little is known about the source of Toxoplasma
gondii infection for humans in India. Rawal from
western India30 reported almost equal seroprevalence
of 37.8 and 37.4 per cent in vegetarians and non-
vegetarians. Limited data are available regarding
seroprevalence of toxoplasmosis antibodies from
India and ranges from 18 per cent in Uttar Pradesh31
to 57 per cent amongst women of child bearing age
and 30 per cent in children in age group of 10-12 yr
in Himachal Pradesh, both north Indian states32.
The coccidian parasite is an obligate intracellular
parasite and exists in three forms: the oocyst, tissue
cyst or bradyzoite (non replicating organism being
responsible for latent disease) and the tachyzoite
(replicating form of the organism causing active
disease). Development of toxoplasmosis is dependant
on host’s susceptibility and immune status. Of the two
types of immunity, humoral immunity with circulating
antibodies is the first to appear and limits extracellular
dissemination of the organism. Further protective
immunity is mediated by CD8+ cytotoxic T cells that
produce interferon-gamma and interleukin-2. The
organism can remain quiescent in the host lifelong
and clinical infections occur only when an
imunosuppressed state leads to parasitic activation.
The majority of the primary cases are
asymptomatic. Progressive loss of cellular immunity
as in HIV causes reactivation of the dormant lesion
in the macrophage system, similar to cryptococcosis
which reaches brain by haematogenous spread to
cause cerebral toxoplasmosis. Toxoplasmosis
develops when CD4 counts fall blow 100 cells/ul.
Predominant neuropathological features of cerebral
toxoplasmosis is multifocal necrotizing encephalitis.
Localization of multiple lesions with ring enhancement
on neuroimaging in basal ganglia, thalamus and fronto-
parietal cortex is similar to cryptococcal lesions, and
suggests haematogenous spread. The predilection of
toxoplasma for the basal ganglia can result in a variety
of movement disorders33. In contrast to cryptococcal
meningitis, the cerebral oedema, encephalitic process
and tissue destruction are significant and responsible
for majority of neurological morbidity in HIV positive
patients presenting with focal brain lesion34. Rupture
of tissue cysts in AIDS patients results in renewed
multiplication of bradyzoites into tachyzoites, which
elicits severe inflammatory reaction. Three
morphological patterns of lesions are produced based
on stage of infection and degree of tissue reaction:
(i) necrotizing abscesses or encephalitis found in acute
stage (less than few weeks duration) seen as poorly
circumscribed necrotic foci with variable
haemorrhage, perifocal oedema, acute and chronic
inflammation admixed with macrophage infiltration,
with numerous tachyzoites and encysted bradyzoites
along the periphery. Vascular thrombosis/fibrinoid
necrosis of vessel wall, with polymorph infiltration,
intimal hypertrophy and tachyzoites demonstrable in
the hypertrophic arterial wall are common, (ii)
organizing abscesses are found in cases treated for
two weeks or more representing chronic lesions
(weeks to months) and are seen as well circumscribed
foci of central necrosis with rim of congestion. In
contrast to the acute phase, the central foci of acellular
necrosis are surrounded by a granulomatous reaction,
tightly packed lipid and haemosiderin laden
macrophages, prominent hypertrophic occlusive
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arteritis with dense lymphocytic cuffing, and only a
few organisms, and (iii) chronic abscesses are seen
in patients treated for a month or more which appear
as small cystic cavities or linear orange-yellow scars
containing lipid and haemosiderin containing
macrophages surrounded by a dense gliotic reaction.
Calcification of vessels occurs and organisms are
rarely found. In addition to producing mass lesions,
CNS toxoplasmosis can present as a diffuse, non
necrotizing, rapidly progressive encephalitis
histologically seen as nodules of microglial cells with
encysted bradyzoites and dispersed tachyzoites within
the nodules. This form is unique AIDS patients.
The pathogenesis of necrosis in toxoplasma
encephalitis is unclear. A curious feature is the
vascular pathology of concentric adventitial thickening
and luminal compromise by endothelial cell
proliferation in small perforator arteries similar to
tuberculous vasculopathy, suggesting a pathogenetic
similarity in evolution of the lesions. The ‘organizing
abscess’ lesions of toxoplasma on gross and
microscopic feature resemble liquefying tuberculoma
and tuberculous abscess causing problems in
discrimination, when there is no prior history of AIDS
or serological evidence of toxoplasmosis.
CNS toxoplasmosis in autopsy series varies from
4-41 per cent. Most have no evidence of systemic
involvement suggesting reactivation of latent infection
in CNS. Striking geographic differences are seen in
incidence of toxoplasma encephalitis between Europe
(17-40.7%), North America (5-14.1%) and Latin
America (34.1%)35. At our Centre, from 1990 when
the first case of HIV was detected, of 113 patients
with focal brain lesions who came to autopsy,
toxoplasmosis was the single most common
aetiological agent (89%), followed by tuberculoma
seen in only 7 per cent and primary CNS lymphoma
(3.6%) (unpublished data). In a study from Mumbai
CNS toxoplasma lesions were seen in 20 per cent of
AIDS cases at autopsy36. In a clinico-radiological
study of 1527 HIV seropositive subjects from Pune,
western India20, toxoplasmosis was the commonest
cause of mass lesions (66%). No case of primary
CNS lymphoma was recorded20.
Post HAART era has altered the picture to a variable
extent in the West, but no information is available as
yet from India, as HAART has been introduced here
only recently.  No case of adult CNS toxoplasmosis
was reported in India prior to the AIDS era, though
toxoplasmosis related congenital anomalies and high
level of antitoxoplasma antibodies in prenatal mothers
has been recognized, especially in northern India36.
Infection by other protozoans like Cryptosporidium
and Plasmodium does occur in AIDS patients. HIV-1
infection and malaria are common, widespread and
overlapping problems in India with HIV being endemic
in many parts of the country where malaria is also
prevalent making an interaction between them of great
public health importance. The association with HIV
does not appear to have significantly altered the
evolution of the disease. In a limited study of pathology
of cerebral malaria, in relation to HIV, the apparently
discernable difference was paucity of microglial
reaction (Durck granulomas) in white matter, but no
significant difference in parasite index (Shankar SK,
personal observation).
The association of opportunistic infections by other
protozoans (Acanthmoeba and Naegleria) in AIDS
have been reported. Pneuomocystis carninii
principally involves the lungs, and rarely retina, bone
marrow, skin, mastoid and small intestine37-39. Till date,
only a single case of CNS involvement in a drug
abuser is on record40 who had co-existing
Toxoplasma and P. carninii cysts within cerebral
abscesses. At our Centre, we have detected only one
case of acanthameba meningoencephalitis41 .
Bacterial infections
Bacterial infections of the CNS are rare in AIDS
patients possibly due to unimpaired neutrophillic
response in AIDS. Mycobacterial infections are the
most common of the bacterial pathogens that cause
CNS involvement in AIDS.
Neurotuberculosis: TBM is the most serious
extrapulmonary manifestation of tuberculosis, and co-
infection with HIV has probably altered the evolution
of the pathological lesion and clinical course. (Most
patients with TBM have a CD4 count <200 cells/µl.
Mycobacterium tuberculosis in association with HIV
is common in the developing world and in intravenous
(iv) drug abusers. The prevalence of CNS-TB varies
SHANKAR et al: NEUROPATHOLOGY OF HIV/AIDS
474 INDIAN J MED RES, APRIL  2005
with endemicity of TB in the population. The highest
rate in a developed country in autopsy series is 1.4
per cent, among whom 52 per cent were drug users42.
In developing countries such as India and Africa, it is
approximately 12 per cent of unselected autopsies
with tuberculoma and tuberculous abscesses
occurring in 6 per cent of cases8,43.
Although Berenguer et al44 from USA noted that
nearly 80 per cent of HIV-seropositive cases of TBM
were IV drug users, in Indian series, not a single case
of IV drug users is on record, and HIV was acquired
by heterosexual contact. Even from north-eastern part
of India, where IV drug abuse is common, no
documented cases of neurotuberculosis with IV drug
abuse and HIV are available. At our Institute
(unpublished data), among the HIV seropositive cases,
21.9 per cent were alcoholics compared to 5 per cent
in HIV negative group. Evidence of pulmonary
tuberculosis at the time of hospitalization was evident
in 48 per cent of HIV-positive group and 17 per cent
in HIV-negative group. Nearly half of the HIV-
positive patients developed TBM, while already on
antituberculous therapy most often for pulmonary
tuberculosis. Generalized lymphadenopathy was found
in 34 per cent in HIV-positive group and 14 per cent
in HIV-negative group which is similar to western
literature44,45. Mean CD4+ cell count was 196/µl in
HIV-seropositive group and 587/µl in seronegative
group46 similar to Western studies47. On cranial CT
scan evidence of cerebral atrophy was observed in
18.8 per cent of HIV-positive cases and 3 per cent in
HIV-negative cases. Focal lesions suggestive of
tuberculomas were noted in 8 per cent of HIV-
seronegative group and 3 per cent of seropositive
group from Bangalore (unpublished data), compared
to higher frequency (15-24%) of tuberculomas
associated with TBM in HIV positive cases from
West44,48. Spinal epidural tuberculosis appears to be
relatively less frequent in India, when compared to
cranial tuberculosis, though this impression needs to
be further substantiated with actual data.
In reports from the West wherein TBM is rarely
encountered, the macro- and microscopic features of
TBM in HIV-seropositive cases are reported to be
no different from HIV-negative cases. In contrast,
in reports from Western India, distinct differences
were noted between TBM in seropositive and
seronegative cases49 with the basal exudates in HIV-
positive cases being serous and relatively
inconspicuous, but yet teeming with acid-fast organisms
in the smear made from basal exudates. Without prior
knowledge of HIV seropositive status, some of the
brains in gross examination can be labelled ‘normal’.
It is difficult to label these as cases of primary infection
of meninges, as they had pre-existing pulmonary
lesions. Even at our Institute, from south India, similar
features were noted, though occasional cases in HIV-
positive group had thick basal exudates (unpublished
data). This could reflect slow evolution of meningitic
process or acute exacerbation of pre-existing pathology
following immunosuppression and fall in CD4 cell count.
Tuberculous arteritis, phlebitis, abscess formation,
cerebral and brainstem infarcts were more frequent in
HIV-positive cases similar to the study from Mumbai49.
Whether these phenotypic differences in pathology of
TBM in West versus East is secondary to differences
in CD4 counts, immune status or the HIV-1 clade C
subtype needs to be probed. In many of the studies
from India, serial CD4 cell count and viral load is not
available due to technical reasons and this forms a
limitation in understanding the evolution of the disease.
Viral infections
Viral infections are frequent complications of AIDS.
The CNS is mainly involved by two groups of viruses:
the herpes family [primarily cytomegalovirus (CMV)
and less frequently varicella zoster (VZV) and herpes
simplex virus (HSV)] and papova virus.
Cytomegalovirus belongs to the Herpes family and
has been identified as a ubiquitous pathogen in several
mammals. The infection predominates in people living
in underprivileged countries and densely populated
areas50 and sexually promiscuous homosexuals51. It
is known to cause encephalitis, ventriculo-
encephalitis, polyradiculitis, radiculomyelitis and
peripheral neuropathies. CMV infection of the brain
has been documented in approximately 30 per cent
of patients with AIDS5, though CMV encephalitis is
a rare clinical diagnosis in patients with HIV52.
It occurs in patients with very low CD4 counts
of <50 cells/µl.  Two distinct clinical and
neuropathological entities of CMV encephalitis has
been recognized53,54. The first is, encephalitis with
dementia, revealing microglial nodules in the grey
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matter of the cortex, basal ganglia and brain stem.
The second form is ventriculo-encephalitis, with
necrosis and leucomalacia in the periventricular zones.
From India no serological or pathological data are
available regarding the prevalence and pathological
spectrum. From NIMHANS, only one case of CMV
ventriculoencephalitis associated with HIV is
recorded during the past ten years41.
Although there is a strong association between
immunosuppression and herpes zoster, only a few
patients with AIDS develop neurological complications
associated with VZV. Patterns of VZV involvement
of CNS in AIDS include ( i) multifocal
leukoencephalitis with and without an inflammatory
vasculopathy55,56 in which multiple partly demyelinating
lesions surrounded by inclusion-bearing
oligodendrocytes are seen in deep white matter
suggesting haematogenous spread of infection;
(ii) bulbar encephalitis or transverse myelitis
secondary to transsynaptic spread to brain or spinal
cord from VZV ophthalmicus, trigeminal, dermatomal
or myotomal infection; (iii) ependymitis/ventriculitis
mimicking CMV infection; and (iv) leptomeningeal
vasculitis or vasculopathy often associated with
haemorrhagic infarcts in brain or spinal cord. Large
arteries involved may show granulomatous vasculitis,
or vascular necrosis and thrombosis with little or no
inflammation. One case of vertebrobasilar thrombosis
causing infarcts in posterior circulation associated
with VZV infection was recorded at NIMHANS.
Another case of multifocal leukoencephalitis caused
by VZV was seen at autopsy in an AIDS patient who
succumbed to cerebral malaria (unpublished data).
Eosinophillic intranuclear inclusions of Cowdry type
A are found in oligodendrocyte, astrocytes, occasional
neurons, ependymal cells, endothelial cells, and
schwann cells. VZV infection can be confirmed by
immunocytochemical/in situ hybridization techniques.
Polymerase chain reaction (PCR) for detecting VZV
DNA in CSF has also been found useful in early
diagnosis of VZV associated neurological disease.
HSV encephalitis does not seem to occur more
frequently in AIDS than in immunocompetent
individuals. Atypical forms of HSV encephalitis are
reported in patients with AIDS with non-necrotizing
encephalitis occurring at sites other than temporal or
frontal lobes, usually involving brain stem and more
slowly progressive than classical HSV encephalitis
with persistence of viral antigen and DNA57. A single
case of HSV encephalitis was observed at our centre
with no discernible haemorrhagic/necrotizing lesions
seen but viral antigen was demonstrable by
immunochemistry41.
Progressive multifocal encephalopathy (PML) is a
fatal, demyelinating disease caused by JC virus in
immunocompromised individuals. Though once
considered relatively uncommon, PML is now
diagnosed more frequently, mainly due to the
association with AIDS, greater awareness among
neurologists and fairly diagnostic imaging
characteristics. Though no definite therapy is available,
introduction of HAART has significantly altered the
course of the disease, enhancing the survival period.
The causative agent, Polyoma virus is considered
to be ubiquitous, the infection usually acquired during
childhood, by sewage contamination similar to
poliomyelitis. Serological studies have suggested that
70-90 per cent of adults have been infected58. The
primary infection has not been associated with clinical
symptoms, the virus remaining latent in kidney, brain,
and peripheral blood lymphocytes59,60. The means of
JC virus transmission is still speculative with most
frequent postulate being respiratory spread. The
prevalence of PML in patients of AIDS has ranged
from 1 to 10 per cent and has been reported as an
AIDS defining illness in 57 per cent of patients
presenting with PML61.
JC virus essentially infects oligodendroglia and
astrocytes and the hallmark is multifocality of the
lesions. Nearly all cases of PML involve the cerebral
white matter, but it may also involve white matter of
cerebellum, brainstem and spinal cord. Histology
reveals basophilic intranuclear inclusions in
oligodendroglia, reactive astrocytosis with ‘tumour
like’ bizarre nuclei in the demyelinating zones. The
lesions characteristically involve subcortical white
matter, extending to the lower layers of the cortical
ribbon. By immunocytochemistry JC viral antigen can
be demonstrated both in the oligodendroglial nuclei
and astrocytic cytoplasm, extending along the
processes. In view of its multifocal nature of pathology,
PML needs to be considered as a differential diagnosis
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in dealing with focal brain lesions. Ammassari et al34
in a series of 281 focal brain lesions, associated with
HIV, reported PML in 18.2 per cent of cases,
toxoplasma encephalitis and primary CNS lymphoma
preceding it. In India, with the advent of the HIV
era, neurologists, based on neuroimaging started
making a diagnosis of PML, though most are not
confirmed by histology or molecular biological
techniques. Recently, JCV was shown to infect
cerebellar neurons resulting in cerebellar degeneration
in some HIV infected patients62. Prior to 2000, at
NIMHANS, not a single case of PML was diagnosed.
Subsequently in 2 yr (2001-2002), histologically and
immunohistochemically confirmed cases of PML
were recognized in four steriotactic biopsies and five
autopsies63. Similarly from western India also based
on clinical and neuroimaging characteristics, cases
of PML, associated with HIV were diagnosed20.
Significant genomic diversity in JCV has been
identified, majority of strains in India and Africa being
essentially similar64. The prevalence of PML in India
and Africa is possibly related to altered modulatory
role of  HIV-1 subtype C, in contrast to HIV-1 B in
Europe and  USA. A sequence diversity in the
regulatory region and nuclear localization region of
Tat amongst HIV-1 clade B and C has been
recognized65. JCV contains sequences in the 5' end
of late RNA species with extensive homology to HIV-
1 TAR (transactivation response element), thus
facilitating Tat activation of JCV promoter. HIV-1
Tat protein can induce regulatory proteins like nuclear
factor Kappa B (NF-KB), NF-1 in microglial cells
which in turn can activate JCV, lying dormant in
oligodendroglia or astrocytes66,67.
The HIV and JCV interaction can be strain
dependent. HIV infection induces a wide variety of
cytokines, chemokines and adhesion molecules in the
brain68,69 and several chemokine receptors in
astrocytes70. These increased expression of
inflammatory mediators, along with Tat induced
monocyte chemoattractant protein (MCP-1)
expression in astrocytes facilitate the migration of
monocytes and lymphocytes into the brain, a
pathogenetic mechanism for HIV associated
dementia. JCV associated dementia could also be
mediated by similar pathway, synergistically
commanding HIV associated cognitive deficits. HHV-
6, another benign oligodendrotropic beta-herpes virus
is found to be  closely associated with JCV71,72. The
differential transactivation potential of various HIV-
1 subtypes on these viruses needs to be explored.
High prevalence of PML in white males in contrast
to African American males suggest racial/genetic
differences73. Whether similar phenomenon is
responsible for low prevalence of PML in India and
sub-Saharan Africa needs further  probing.
CNS neoplasms
In the western literature, the incidence of primary
central nervous system lymphoma (PCNSL) in HIV
infected population is documented to be on the rise.
In HIV infected adult patients, the incidence of this
neoplasm is 1000-3000 times more common74
occurring in 2-5 per cent of patients with AIDS75.
PCNSL associated with HIV-1 infection is virtually
multifocal76 and Epstein-Barr virus is almost always
found in the tumour77. Despite marked increase in
the number of AIDS cases in India and other Asian
countries, very few cases of HIV associated neoplasia
are recognized. During the past 10 yr in Bangalore,
south India among 29 cases of PCNSL tested for
HIV, three were positive. From north India among 80
cases of PCNSL, not a single case was positive for
HIV78. In Australia, the cumulative incidence of non-
Hodgkin’s lymphoma (NHL) among AIDS patients
is 10 per cent, one-fifth of them having primary CNS
lymphomas, manifesting with advanced
immunosuppression79. Recent studies recorded
malignant lymphomas in biopsy/necropsy specimens
in 4 per cent from Northern Thailand, 4.3 per cent
from Papua New Guinea and 5.6 per cent from Japan
and 2.3 per cent from Indonesia80. It is possible that
in developing Asian countries, lymphoma-related
lymphadenopathy may have been diagnosed as
infective lymphadenitis, because of high prevalence
of infections and clinical bias.
Kaposi’s sarcoma, a vascular neoplastic lesion that
has come to scrutiny following the association between
homosexuality and HIV infection, rarely involves
nervous system, that too as a metastasis from
extracranial site. Till date, only one case of cutaneous
Kaposi sarcoma, without CNS metastasis in a
heterosexual male has been reported from India8.
Whether it is related to low prevalence of HHV-8
infection in Indian population needs to be studied.
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HIV-specific nervous system changes
In contrast to secondary injury to the brain
following HIV associated opportunistic infections,
widespread CNS injury is caused by HIV per se,
referred to as primary pathology. This primary
pathology includes a range of inflammatory disorders
as well as neuronal loss along with dendritic damage
and synaptic loss.  During the early asymptomatic
phase, non specific changes like astrocytosis,
perivascular lymphocytic cuffing, diffuse and variable
degree of microglial proliferation are described81. At
this stage neuronal loss is not a feature82. This is a
stark contrast to significant frontal lobe neuronal loss
of 38 per cent in symptomatic HIV cases83. The HIV
specific pathology manifests in different phenotypic
forms, during the course of illness. This manifestation
appears to be controlled by trafficking of HIV virus,
within infected immune cells and as free virus from
the peripheral blood to the central nervous system
crossing the blood brain barrier. The process is
complex and dynamic involving many cell types (like
microglia/macrophages, astrocytes, vascular
endothelial cells and rarely neurons), cell surface
receptors (CXCR4, CCR5), the turn over kinetics and
migratory capacity of the cells84. Principal sites of
productive HIV infection of CNS are microglia/
macrophages, facilitated by surface receptors85. In
the study from the West, the macrophages are found
to show shift of CXCR4 receptor to CCR5 during the
course of disease, correlating with the formation of
HIV-associated multinucleated giant cells. This
receptor shift has been described to be lacking in the
Indian HIV strains probably modifying the course of
the disease86.
HIV encephalitis: HIV encephalitis occurs in 15-40
per cent of cases with AIDS87, microscopically
characterized by multiple foci of inflammatory cells,
including macrophages, microglia and multinucleated
giant cells. The multinucleated giant cells are the
histological hallmark of HIV encephalitis, harbouring
the virus. The prevalence of HIV encephalitis and
presence of multinucleated giant cells are considered
to be uncommon in India, though no systematic studies
are available.
HIV encephalopathy, characterized by diffuse,
symmetric white matter demyelination, astrocytosis
and presence of microglia and multinucleated giant
cells could be a part of spectrum of HIV specific
brain pathology,  overlapping with HIV
encephalitis83. Curiously in the autopsy material
from south India, multiple foci of demyelination in
the white matter was noted in cases of HIV
associated cryptococcal and toxoplasma infections,
especially close to vessels. It is not clear if this
feature is a reflection of HIV leucoencephalopathy
or related to vasculopathy associated with
opportunistic infections. Whenever ring enhancing
lesions are observed on imaging, empirically
antitoxoplasma drug regimen is initiated. In some
of the autopsied cases of toxoplasma encephalitis
and cryptococcal meningitis multiple burnt out scars
are seen. Similarly in the brains with these two
opportunist ic  infect ions large zones of
demyelinat ion are seen similar  to  HIV
leucoencephalitis. How these white matter lesions
contribute to the cognitive dysfunction is not clear.
Vacuolar leucocephalopathy is occasionally found
in some of these cases. Similarly demyelination of
the posterior columns of the spinal cord was observed
in nearly half of the autopsied cases, while vacuolar
myelopathy was rare. However, none of the cases
had neurological deficits of myelopathy (S.K. Shankar,
unpublished data)..
HIV encephalitis is known to be accompanied by
depletion of specific population of neurons in
neocortex, limbic system and basal ganglia. The
selective damage to neuronal population in the frontal
cortex88 in association with dendritic abnormalities
may be the pathological basis for frontal lobe
neuropsychometric abnormalities and HIV associated
dementia. The mechanisms of neurotoxicity are
considered to involve vulnerability of specific neuronal
population to viral proteins, cytokines secreted by
activated macrophage/microglial population altered
calcium binding proteins and activation of glutamate
receptors in the neurons89,90. HIV-1 proteins gp120
and Tat block the response of cells to growth factors,
platelet derived growth factor (PDGF)91 and nerve
growth factor (NGF)92. In addition, Tat may be directly
toxic to neurons93, may activate glial cells to release
cytokines94 or alter release of fibroblast growth factor-
1 (FGF-1) causing deleterious effect on survival of
neuronal populations95.
SHANKAR et al: NEUROPATHOLOGY OF HIV/AIDS
478 INDIAN J MED RES, APRIL  2005
The prevalence of HIV associated dementia (HAD)
among otherwise asymptomatic subjects is estimated
to be 15-30 per cent in USA and Europe96,97. In
contrast, an unusually low incidence of HAD has been
reported in India98,20. Usually low prevalence of HAD
in underdeveloped and developing countries have been
attributed to underdiagnosis, short life expectancy and
short survival following HIV infection associated with
opportunistic infections. However from a tertiary care
neurological centre, six cases of HAD were found
among 427 HIV-infected individuals, suggesting that it
may not be an artifact (unpublished data). However, it
is important to point out that psychometry was not
carried out routinely in all the cases, thus necessitating
further prospective systematic studies. In an attempt
to identify the viral determinants for this low prevalence
of HAD in India caused by HIV-1 clade C in contrast
to HIV-1 clade B associated high prevalence in the
West, variation in Tat protein sequence and its influence
on  monocyte chemotaxis were studied99. Conservation
of cystine at position 31 in non-subtype C viruses (CC)
was observed, while in subtype C, it was replaced by
serine (CS). The ‘CS’ variant was found to be
defective for monocyte chemotactic activity without
loss of transactivation property, while both functions
were preserved in non-C HIV-1 subtypes. Though the
evidence is not conclusive, this could be one of the
factors for the low incidence of HIV-1 encephalitis
and HAD in Indian subcontinent.
Till date, no neuropathological data are available in
literature related to HIV encephalitis and HAD in HIV-
1 clade C infected individuals. During the initial phases
of HIV/AIDS, the opportunistic infections due to
immunocompromised  state took the centre stage,
accounting for the high mortality. Slowly specific HIV
induced neuropathology, never seen prior to the AIDS
epidemic and found only in HIV-infected individuals
without evidence of another cause was recognized100.
Productive infection of the CNS by HIV, monocyte/
macrophage/microglial cells taking the active role and
astrocytes a passive role in pathogenesis has been
demonstrated by  various virological and morphological
techniques. Pathological basis of HIV dementia still
remains a subject of debate, while HIV
leukoencephalopathy, HIV encephalitis and diffuse
poliodystrophy have been well characterized101. It
seems likely that HIV dementia represents a specific
neuronal dysfunction resulting from the compounding
effect of several mechanisms, some of them being
reversible.
Neuropathology of paediatric AIDS
Neurological manifestations in paediatric cases are
commonly secondary to immunodeficiency or direct effect
of HIV on the nervous system102. Cerebrovascular
diseases and lymphomas are most common, and CNS
lymphomas are mostly associated with Epstein Barr virus
(EBV) infection. Opportunistic CNS infections are
uncommon, with monilial and cytomegaloviral infection
being the common ones. Unlike adults, cerebral
toxoplasmosis is rare in children and haemophiliacs.
Direct effects of HIV-1 on CNS in children manifest as
microcephaly, diffuse gliosis, basal ganglia mineralization
and HIV encephalitis. HIV related encephalopathy
affects >50 per cent of children with AIDS103 with
characteristic multinucleated giant cells. Progressive
encephalopathy in HIV-1 with its classical triad of
microcephaly with brain atrophy, delayed developmental
milestones and progressive motor dysfunction should be
discriminated from metabolic disorders with progressive
cerebral degeneration in developing countries. Certain
neuropathological features are unique to paediatric HIV
infection/AIDS. Mineralization of small penetrating
vessels in basal ganglia are the most common findings
seen in more than 90 per cent of cases at autopsy104.
Its pathogenesis is unknown but believed to be related
to transient alteration in blood- brain barrier. Other
vascular changes unique to paediatric AIDS include
inflammation of intraparenchymal vessels resembling
a vasculitis, intimal thickening of larger leptomeningeal
vessels and occasionally a granulomatous vasculitis
causing infarcts in brain.
The paediatric CNS appears to be unusually
susceptible to even low levels of HIV-1 infection.
No neuropathological studies on paediatric AIDS are
available from India. At our Centre, we have seen
one case each of cryptococcal meningitis and
toxoplasma encephalitis in two children who
succumbed to AIDS (unpublished data).
Highly active antietroviral therapy (HAART tri-
or multi-therapies)
HAART has dramatically improved the course and
prognosis of HIV disease in many of the developed
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countries where this treatment is widely available.
Though the most dramatic benefit of HAART
restored functional immune system affording
protection against opportunistic infections, improved
neuropsychological performance, its effect on
cognitive disorders/dementia is less satisfactory105,106.
The antiretroviral treatment is found to reduce viral
load and enhance circulating T lymphocyte counts.
But viral mutations leading to viral resistance, side
effects of the drug and lack of compliance to therapy,
especially in developing countries remain major
problems. The restored immune function has reduced
the effect of opportunistic infection. In India,
antiretroviral therapy has been initiated around
1998 depending on the availability and affordability
of the drugs.
Post-HAART era
In the West because of significant improvement
in control of opportunistic infections and longer
survival of the patients, autopsies on AIDS cases have
decreased dramatically, resulting in non-systematic
studies107-109. There was an overall decrease of
cerebral toxoplasmosis, cytomegalovirus encephalitis
and HIV encephalitis, while the incidence of PML
and malignant non Hodgkin lymphoma (NHL) has
remained unchanged, though survival period is
enhanced. Severe leukoencephalopathy with intense
perivascular  lymphocytic and histiocytic infiltration
is described following HAART, probably as a
response to immune reconstitution110.
In India, antiretroviral therapy was initiated in
1996, in a limited scale, both to adults and antenatal
mother to prevent mother-to-child transmission. No
neuropathological observation from the brains of
patients who received antiretroviral therapy is
available from India to compare with West, though
clinically follow up for maximum period of four to
five years is available. Clinicians consider immune
reconstitution syndrome whenever the patient on
antiretroviral therapy deteriorates after initial
response. Unfortunately, in many of these cases
sequential CD4/CD8 counts and viral load are not
available for objective evaluation. In near future with
the availability of facilities, the management and follow
up strategies are expected to improve for systematic
analysis.
Neuromuscular disorders in HIV/AIDS
The demonstration of direct involvement of the
CNS by HIV led many workers to seek a similar role
for the virus in the peripheral nervous system.
In fact, peripheral neuropathies were among the first
neurological conditions to be described in AIDS2, and
is the most frequent complication of HIV infection.
The reported incidence varies in different series from
15 to 50 per cent111. However, subclinical evidence
based on electrophysiologic studies has been reported
in 50 to 90 per cent of patients with AIDS112 while
autopsy studies demonstrate pathological
abnormalities of the nervous system in general in over
95 per cent of patients dying of AIDS6,113. With the
introduction of HAART although CNS involvement
by opportunistic infections and HIV associated
dementia have declined significantly, incidence of
peripheral neuropathies is actually increasing owing
largely to the neurotoxic effect of antiretroviral drugs.
Classifications of HIV related peripheral
neuropathies have subsequently been evolved based
on the different clinical syndromes that occur at
different stages of HIV infection. During early stages
of HIV infection when there is no
immunosuppression, patients are more susceptible to
immunological disorders. In the later stages when
immunosuppression supervenes, opportunistic
infections and tumours cause various peripheral nerve
syndromes. Additionally, peripheral neuropathies can
also result from neurotoxic effects of drugs or
malnutrition.
The clinical presentations can encompass the entire
spectrum of peripheral nerve disorders. The spectrum
of neuropathies described include inflammatory
demyelinating neuropathy (IDP), distal symmetric
sensory polyneuropathy (DSPN) which is often
painful, progressive polyradiculopathy, mononeuritis
and mononeuritis multiplex and autonomic neuropathy.
The manifestation of  neuropathy is related to the
stage of the disease with the inflammatory
demyelinating neuropathies occurring early at the time
of seroconversion, followed by DSPN, polyradiculitis
and autonomic neuropathy at the time of full blown
AIDS. Mononeuritis multiplex can occur at any stage
of the disease secondary to vasculitis, cytomegaloviral
infection, lymphoma or cryoglobulinaemia.
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Peripheral nerve syndromes reported to occur at
the time of seroconversion include acute inflammatory
polyradiculopathy (AIDP)114,115, lower motor neuron
facial palsy often associated with aseptic meningitis115
and bilateral brachial neuritis116. All these syndromes
are self limiting and no neuropathological studies are
available. These could be evidence of early
neurotropism of the HIV virus as it has been isolated
from CSF in some cases114,115. Both acute (AIDP)
and chronic inflammatory demyelinating
polyradiculopathy (CIDP) have been described to
occur in HIV seropositive cases117-120. Except for the
presence of CSF pleocytosis (up to 300 cells/mm3 in
AIDP and up to 50 cells/mm3 in  CIDP) the clinical
manifestations, course and response to treatment are
identical to that seen in HIV seronegative
individuals117. The pathogenesis too may be similar
as circulating autoantibodies reactive with peripheral
nerve components have been reported121,122 and the
patients respond to different modes of
immunomodulation such as plasmapheresis,
corticosteroids and intravenous immunoglobulins.
Neuropathological studies are limited to sural or
superficial peroneal nerves117-120,  which show
variable inflammation, subperineurial oedema, de/
remyelination best seen on teased fibre studies and
axonal degeneration. Cornblath et al117 demonstrated
by immunohistochemistry that most of the
inflammatory infiltrate that surround endo/epineurial
vessels (<80 µm) are T cells. Attempts to localize
the HIV virus in the nerves by in situ hybridization
have been uniformly unsuccessful but immune
deposits have been seen in nerve biopsies. The virus
was cultured from one nerve but its significance is
unclear as it could be a circulating macrophage
containing the virus9,117. This makes a direct role for
HIV in the pathogenesis for AIDP or CIDP unlikely.
Inflammatory demyelinating neuropathies (IDP) can
also occur later on at the stage of AIDS related
complex (ARC) and AIDS. IDP when associated
with low CD4 counts is usually secondary to CMV
infection123.
Vasculitic neuropathy: Of the various peripheral
nerve syndromes in HIV/AIDS, vasculitis of the
peripheral nerve occurs in up to 3 per cent of patients
with ARC or full blown AIDS124. In HIV/AIDS,
vasculitis of the peripheral nerve may be the first sign
of HIV infection. Its occurrence has been noted even
in asymptomatic seropositive patients118. In most
patients the vasculitis is not systemic. Pathologically,
there is marked involvement of the microcirculation
with inflammation and fibrinoid necrosis of arteries
smaller than those that are typically affected in
polyarteritis nodosa. Inflammatory cells have been
immunologically characterized as CD8+ T cells and
macrophages. Le Faucheur et al125 studying 100
patients with HIV associated peripheral neuropathy
found that the CD4 counts in patients with
mononeuritis multiplex (125 cells/µl) were lower than
those with IDP (194 cells/µl) and higher than patients
with DSPN (108 cells/µl in mild and 66 cells/µl in
severe form of the disease).
Vasculitis associated with CMV is seen in the later
stages of HIV infection and is distinct both clinically
and histopathologically by its rapid progression and
involvement of endoneurial vessels, in the form of
necrotizing vasculitis with polymorph infiltration. The
CD4 counts are usually less than 50/µl. CMV
inclusions have been seen in the endothelial as well
as inflammatory cells. CMV antigen was not
demonstrable by immuno-histochemistry in any of the
cases studied at our Centre.
The pathogenesis of vasculitis in HIV infection is
largely speculative. The finding of immunoglobulin
deposits, complement as well as immune complexes
on the vessel wall in some studies suggests an immune
mediated disorder126-128. Circulating immune
complexes directed against the HIV virus itself or
induced by the opportunistic infections are commonly
observed in patients with AIDS. These complexes if
deposited on vascular walls could conceivably initiate
vascular injury as in polyarteritis nodosa. A direct
role by viral invasion of the peripheral nerve was also
considered following isolation of the virus from
peripheral nerve homogenates9,129,130. But the viral
antigens have never been detected in the peripheral
nerve either by PCR131 or by immunohistochemistry
even in the nerve from which the virus was
isolated129,132,133. Gherardi et al134 reported evidence
of HIV viral replication in perivascular macrophages
in two patients with nacrotizing vasculitis and AIDS
by in situ hybridization.
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The other forms of peripheral nerve involvement in
HIV infection include DSPN which is the most common
form of peripheral neuropathy in AIDS. While clinical
and electrophysiological abnormalities are detected in
up to 35 per cent  of patients135, pathological changes
have been found in all patients dying of AIDS136.
Histologically, most workers describe axonal loss with
little inflammation. Simpson & Wolfe137 studying 165
cases noted that the frequency of DSPN varied
inversely with CD4 counts below 200/µl. Rance et al138
demonstrated degeneration of the gracile tract in the
spinal cord and proposed that DSPN is a dying back
neuropathy secondary to ganglionitis/gracile tract
degeneration. A direct effect by the virus was also
considered following isolation of the virus from the
peripheral nerve in a single case9 and demonstration of
virus like particles in the axoplasm of the nerve fibre
in another case139 by electron microscopy.  Vital et al140
reported HIV viral replication in perivascular
macrophages in two patients with DSPN suggesting
that these could be local sites for replication of the
virus. Other factors implicated include the neurotoxic
effects of circulating gp120, local release of tumour
necrosis factor α and other T-cell and macrophage
related cytokines. In fact, tumour necrosis factor α is
known to enhance HIV replication in vitro and also
cause tissue damage in peripheral nerve141. The
pathogenesis of vasculitis in HIV/AIDS is therefore
possibly a complex interaction between immune
complexes, cytokines that induce the macrophages to
enhance HIV replication and initiate the pathway of
vascular injury resulting in vasculitis.
An uncommon form of HIV associated neuropathy
that is treatable (with zidovidine and corticosteroids)
and enters the differential diagnosis of DSPN is the
diffuse infiltrative lymphocytosis syndrome (DILS).
It is a multisystem disorder that mimics Sjogren’s
syndrome. Peripheral nerve manifestations include a
painful, sensorimotor axonal neuropathy142. Nerve
biopsies show characteristic angiocentric infiltrates
of CD8 cells without necrotizing arteritis.
Interestingly, the HIV proviral load in whole nerve
extracts in DILS are more than 100,000 fold higher
than that in other HIV associated neuropathies. In
contrast, the viral load in plasma is low, suggesting
local viral replication. Gherardi et al143 by PCR
techniques demonstrated that the CD8 cells are
polyclonal and hence not lymphomatous.
Toxic neuropathies : Nucleoside analogues
Zalcitabine (ddC) and Didanosine (ddI) and Stavudine
(d4T) have been shown to cause a dose-dependant
neuropathy. Zidovidine also a nucleoside analogue
causes a myopathy but not a neuropathy.
At NIMHANS, Bangalore, we have studied 15
cases of peripheral neuropathy as the presenting
manifestation of HIV. CIDP was seen in five, which
included multifocal motor neuropathy with conduction
blocks in one case. Vasculitic neuropathy with
necrotizing large vessels vasculitis indistinguishable
from collagen vascular disease was seen in four144.
Three presented with painful distal symmetric
polyneuropathy without evidence of CMV infection.
Two of these cases had received antiretroviral
therapy. By electron microscopy, virus–like particles
were demonstrable within the schwann cell cytoplasm
and perivascular macrophages in one case of
necrotizing vasculitis. However, immuno-
histochemically HIV antigen was not detectable
probably due to the low viral density and antigen load,
which is in keeping with most studies in literature.
Diffuse infiltrative lymphocytosis syndrome has not
been described from India. Wadia et al20 from Pune
reported 128 cases of peripheral neuropathies
associated with HIV wherein herpes zoster
(63 cases) and predominantly sensory neuropathies
(51 cases) were the commonest forms.
Subclinical involvement of the peripheral as well
as central nervous system is being increasingly
documented by electrophysiological studies. At our
Institute, 20 asymptomatic HIV seropositive subjects
were evaluated with Mini Mental Status Examination
(MMSE), EEG, nerve conduction and multimodality
evoked potential studies145. Four subjects had MMSE
score of less than 23 suggesting cognitive impairment
though they were functioning normally. EEG was
mildly abnormal in eight cases. Brain stem auditory
evoked potentials (BAER) studies showed peripheral
auditory pathway involvement in 23.5 per cent of
subjects. Somatosensory evoked potentials (SSEP)
was abnormal in two with delay in N20 latency. Nerve
conduction studies showed significantly decreased
mean nerve conduction velocity (NCV) in median and
sural nerves compared to controls. Hence long term
follow-up studies are essential to understand
significance of these studies.
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Electrophysiological studies have also demonstrated
abnormalities in visual pathway even in the absence of
visual symptoms. From autopsy studies at our
Institute146 the pathological changes in the optic nerves
were studied in the subclinical cases. Axonal pathology
was the cardinal finding in addition to demyelination
that corresponded to the prolonged P100 latencies in
the visual evoked potentials recorded antemortem in
these patients. Additionally, cryptococcal parenchymal
infiltration causing sectoral destruction of optic nerve
was also found not commensurate with the degree of
electrophysiological abnormality146.
Myopathies : Myopathy is a well recognized
complication of AIDS and can occur in three main
forms; polymyositis, nemaline rod myopathy, and
zidovidine induced myopathy. Polymyositis is the most
common of the AIDS-associated myositis, and maybe
the presenting sign of HIV infection147. Inflammatory
cell infiltrates of lymphocytes, macrophages, atypical
histiocytes, and occasionally multinucleated giant
cells are reported. HIV virus has not been identified
in the myofibres but presence of viral antigens
within infiltrating CD4 cells was shown by
immunohistochemistry though in situ hybridization
studies were negative147.
The pathological features of the nemaline rod
myopathy occurring in patients with HIV infection are
identical to the adult onset nemaline myopathy111,148.
Zidovidine used in the treatment of AIDS can
cause myalgia in up to 8 per cent of patients139 which
resolves on discontinuation of the drug. Muscle
biopsies show ragged red fibres indicative of
mitochondrial damage, which disappear on
discontinuing the drug. Though clinicians do see cases
of myopathy and myositis associated with HIV/AIDS,
no systematic studies are available from India.
At NIMHANS, Bangalore, one case of
amyotrophic lateral sclerosis (ALS) - like disorder
with HIV clade-C was detected150. ALS-like disorder
in HIV is extremely rare, with only seven cases being
recorded in literature. Its importance lies in the
reversibility of the disorder following antiretroviral
therapy151. The cause for anterior horn cell
dysfunction remains unknown. As the HIV virus has
not been known to directly infect neuronal cells152, it
is speculated that damage to anterior horn cells could
be due to glutamate mediated excitotoxicity, or direct
neurotoxic effect of gp120 and Tat protein of HIV.
Immune mediated mechanisms has also been
suggested following detection of anti-asialo GM1
antibody in ALS-like disease associated with HIV153.
The neuromuscular junction has been considered to
be spared by the HIV virus. However at our Centre,
three cases of myasthenia gravis like syndrome
associated with HIV are noted. Sporadic reports of this
association have also been reported in Western literature.
Conclusions
The spectrum of HIV associated complications
reported from India - south India (Bangalore), western
India (Mumbai and Pune) appears to be different from
the West. The differences could relate to variations in
HIV clade subtype. Large, systematic autopsy studies
correlating with clinical aspects need to be documented
for comparison with Western data. Unfortunately
autopsy studies are dwindling due to phobia on part of
pathologists to carry out autopsies on HIV cases. With
the National policy of providing antiretroviral therapy
to antenatal mothers and adult patients with HIV/
AIDS, a new cohort of patients is emerging with altered
biology of infection confusing the clinical picture. With
passage of time, these patients need to be evaluated in
the light of new knowledge emerging following specific
therapy and compare with the cohort which did not
receive antiretroviral therapy. An intermediate cohort
of patients who received the HAART for sometime
and discontinued the therapy  needs to be evaluated
separately.
The following are the researchable issues necessary
to understand the biology of neuroAIDS in India with
its unique spectrum of opportunistic infections, and
difference in clade subtype: (i) The spectrum of
opportunistic infections and their pathomorphological
features modulated by multiple infections in association
with clade subtype C; (ii) Pathology of HIV/AIDS in
paediatric age group to correlate with cognitive
dysfunction/scholastic performance in long term
survivors; (iii) Spectrum of neuropathological lesions
in IV drug abusers in India with special emphasis on
the influence of HIV subtype/recombinant strains on
the evolution; (iv) Neuropathology of HIV associated
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cognitive dysfunction/dementia; (v) Neuropathology of
HIV encephalitis/encephalopathy with special emphasis
on viral load and macrophage function; (vi) Alteration
in pathobiology of HIV related complications with
immune reconstitution induced by treating opportunistic
infections even without HAART; (vii) Neuropathology
of HIV/AIDS in the heralding era of HAART therapy
in India; (viii) Role of host genetic factors in
susceptibility to neurological manifestations of HIV
infection; and (ix) The effect of antiretroviral therapy
in antenatal mothers and their influence on evolution
of pathological lesions in paediatric AIDS especially
HIV encephalopathy/HIV encephalitis.
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